Highlights d IL-1 induces recruitment of NF-kB p65 to >1,000 mostly intergenic sites d IL-1 activates more than 400 enhancers that show inducible p65 binding and H3K27ac 
Correspondence michael.kracht@pharma.med. uni-giessen. de In Brief Jurida et al. identify the protein kinases TAK1 and IKK2 and the transcription factor NF-kB p65 as master regulators that prime and control the genome-wide activation of interleukin 1-induced enhancers and promoters of inflammatory genes at the level of chromatin.
Accession Numbers GSE64224 GSE52470

INTRODUCTION
Interleukin 1 (IL-1) is a prototypic pleiotropic cytokine that strongly induces local and systemic inflammation (Dinarello et al., 2012) . Evidence in humans shows that dysregulation of IL-1 is sufficient to drive the entire systemic inflammatory response, thus demonstrating that this cytokine is at the apex of inflammatory cascades (Aksentijevich et al., 2009) . At the cellular level, the main effect of IL-1 is the rapid reprogramming of inflammatory gene expression (Schmitz et al., 2011; Weber et al., 2010) .
A central regulator of this gene response in the cytoplasm is the protein kinase TAK1, which is activated by proinflammatory cytokines (IL-1, tumor necrosis factor [TNF] ), transforming growth factor-ß (TGF-ß), stressors, and by various toll-like receptors (TLRs) (Sakurai, 2012) . One major role of TAK1 is to phosphorylate mitogen-activated protein kinases (MAPKs), which then activate individual p38 and JNK MAPK pathways (Ninomiya-Tsuji et al., 1999) . Hence, the kinase is upstream of several transcription factors (TFs) such as Jun or ATF family members, which are all substrates of MAPKs (Shaulian and Karin, 2002) . Also, the TF NF-kB is activated by TAK1-mediated signals on a pathway involving TAK1-mediating activation of IkB kinases (IKKs) (Sakurai et al., 1999) . These, in turn, phosphorylate the cytosolic inhibitor IkBa and enable its ubiquitin/proteasome-dependent destruction, thus allowing nuclear translocation of NF-kB (Hayden and Ghosh, 2008) . The NF-kB p65 subunit has the strongest transactivation potential and its activity is also controlled by many posttranslational modifications including IKK-mediated phosphorylation of the p65 C-terminal transactivation domain at S536, thereby providing an additional mechanism for fine-tuning NF-kB transcriptional activity (Perkins, 2012) . Thus, TAK1 is an apical and global regulator of multiple AP-1 family members and of the NF-kB pathway, but the consequences of TAK1 activity on nuclear events and chromatin binding of TFs have not yet been defined.
Enhancers are gene regulatory elements that control the activity of promoters independent from location, distance, or orientation (Pennacchio et al., 2013) . Enhancers are vital for lineage determination and maintenance of cell types by organizing the recruitment of lineage-specific transcription factors, which provide crucial control of cell-specific genes . Accordingly, enhancers are characterized by specific chromatin states and nucleosomal depletion. Recent evidence shows that active enhancers are associated with characteristic chromatin signatures, most importantly H3K4me1, p300 acetyltransferase occupancy, and H3K27 acetylation (Flintoft, 2013) . High-resolution studies of these marks revealed that enhancers are highly abundant gene regulatory elements with recent estimates ranging from 25,000 to several hundreds of thousands (Zhu et al., 2013; Shen et al., 2012) . Recent work in murine macrophages unraveled PU.1-dependent lipopolysaccharide (LPS)-regulated enhancers, providing support for the dynamic nature of the enhancer repertoire in innate immune cells (Ostuni et al., 2013) . Comparable information on enhancer regulation by inflammatory cytokines, which are vital executers of innate immune functions in most tissues, is lacking.
Because the nuclear signaling network utilized by IL-1 is largely unexplored, we analyzed IL-1-induced chromatin signatures and TF binding at the genome-wide level. We identified 47,609 p65 peaks of which 1,264 were regulated by IL-1. The majority of p65 recruitment occurred at intergenic regions of unknown function. Additionally, we discovered 35,130 enhancers including 1,575 IL-1-inducible enhancers. A subgroup of 410 enhancers shows IL-1-inducible H3K27ac and p65 recruitment and is found upstream of cytokine-induced genes. The activation of this type of IL-1-induced enhancers was fully dependent on the kinase activity of TAK1 and IKK2 and on the presence of NF-kB p65. The TAK1-p65 pathway also regulates the recruitment kinetics of a number of AP-1 factors to both promoters and enhancers. The concerted and synchronized activation of IL-1-driven enhancers provides a unifying molecular mechanism for the rapid and strong upregulation of inflammatory genes evoked by this cytokine.
RESULTS
Identification of IL-1-Regulated Intergenic Enhancers Flanking the CXC Chemokine Cluster on Chromosome 4
To identify the number of IL-1-induced genes in epithelial cells, KB cells were stimulated for various periods of time with IL-1, followed by the analysis of gene expression by microarrays. These experiments showed the IL-1-inducible and time-dependent mRNA expression of 241 genes ( Figure S1A ; Table S1 ) and thus indicate that this cell line is well suited to study IL-1-dependent transcription and chromatin regulation. To address the question of which chromatin-based processes accompany IL-1-induced and p65-dependent gene expression, we performed chromatin immunoprecipitation sequencing (ChIP-seq) experiments with antibodies recognizing the NF-kB p65 protein and chromatin marks typical for active promoters or enhancers as described above (H3K9ac, H3K4me1, and H3K27ac). In addition, genome-wide localization of IL-1-triggered transcripts and ongoing transcription were determined by RNA sequencing (RNA-seq), or by ChIP-seq using antibodies directed at RNA polymerase II (Pol II) and by measuring the serine 5 phosphorylated form of Pol II (P(S5)-Pol II), which occurs during transcription initiation ( Figure 1A ).
For the analysis of ChIP-seq data, we initially focused on a gene cluster containing the highly regulated chemokine genes IL8 (CXCL8), CXCL1, 2, and 3 ( Figure S1B ). These chemokines lie within a genomic region spanning 0.4 Mb of chromosome 4. This region showed strongly regulated p65 binding immediately upstream of the transcriptional start sites (TSSs) of IL8, CXCL1, 2, and 3, reflecting p65 recruitment to canonical NF-kB sites within the promoters of these genes ( Figure 1A , marked by dotted boxes). In addition, we found strongly induced p65 peaks located in two intergenic regions flanking the IL8 and CXCL2 genes ( Figure 1A , marked by solid boxes). RNA-seq and Pol II ChIP-seq analyses showed no signs of ongoing transcription of these intergenic regions ( Figure 1A ). Repressive chromatin marks such as H3K9me3 were absent, in agreement with the biological need to immediately express these chemokine genes in precarious situations. The histone mark H3K9ac was already seen in unstimulated cells and IL-1 treatment augmented this modification at all p65 sites ( Figure 1A ). Small peaks of basal H3K27ac were found at the promoters of transcribed genes (Figure 1A , dotted boxes). Significantly stronger basal H3K27ac marks were found in the regions surrounding the intergenic p65 peaks ( Figure 1A , solid boxes). After IL-1 stimulation of cells, H3K27ac levels at these regions increased even further (Figure 1A , solid boxes). Small areas of basal H3K4me1 were found at promoters ( Figure 1A , dotted boxes), whereas very strong signals occurred at intergenic regions occupied by p65 ( Figure 1A , solid boxes). However, H3K4me1 marks were not regulated by IL-1 ( Figure 1A , solid boxes). In comparison, inspection of an unrelated genomic region that did not contain IL-1-regulated genes showed strong but comparable H3K9ac, H3K27ac, and H3K4me1 signals as well as many nonregulated p65 peaks (Figure S2A) . These data show that IL-1-induced gene regulation involves a specific pattern of regulated chromatin marks in association with p65 binding whose major features are summarized in Figure 1B . Moreover, these data suggest that IL-1 specifically operates through a dual mechanism, which involves p65 binding to individual gene promoters and additionally p65 association with putative intergenic enhancers marked by strong H3K4me1 and regulated H3K27ac signals flanking clusters of highly coregulated genes.
High-Resolution Mapping of Intergenic and TSS-Associated p65 NF-kB Binding Sites To find out whether the patterns of p65 binding and chromatin modifications described above are restricted to the particularly strongly regulated chemokine locus on chromosome 4 or whether they also occur for other IL-1-regulated genes, we further analyzed the nuclear and genomic distribution of p65. In KB cells, about 15%-20% of total p65 protein is present constitutively within the nucleus whereby the insoluble fraction (N2) that is stably associated with chromatin accounts for only about 5% (Figure 2A ). In line with its capacity to activate the canonical TAK1-IKK2-NF-kB pathway, IL-1 treatment strongly increased the amount of p65 in both the soluble (36%) and the insoluble (15%) fractions resulting in a redistribution of about 50% of total p65 to the nucleus within 1 hr of cytokine exposure ( Figure 2A ). IL-1 also induced phosphorylation of p65 at S536 and nuclear translocation of the p50 subunit indicating that the cytokine controls NF-kB signaling to chromatin through multiple steps ( Figure 2A ). To get further insight into the mechanisms operating downstream of nuclear translocation of p65, the ChIP-seq data sets were analyzed at the genome-wide level. In total, we identified 47,609 distinct p65 peaks. Constitutive p65 binding occurred at 46,345 genomic locations, whereas 1,264 p65 peaks were regulated by IL-1 by at least 2-fold ( Figure 2B ). Compared to those sites showing constitutive binding, IL-1-inducible peaks were characterized by much lower basal chromatin binding and increased recruitment after induction (A) Human epithelial KB cells were stimulated with IL-1 for 1 hr or were left untreated. Then chromatin or total RNA was prepared, and RNA-seq or ChIP-seq experiments were performed using the indicated antibodies, and read coverage was determined. Shown are coverage profiles across the human CXC chemokine (legend continued on next page) ( Figure 2B ). About 50% of all constitutive binding sites and almost 75% of all IL-1-inducible sites were located >20 kb upstream of the next annotated gene ( Figure 2C ). Only 2.93% (728 of 24,828 sites) of all p65 peaks located >20 kb upstream of the next TSS were overlapping with Pol II and P(S5)-Pol II peaks, whereas 76% (7,405 of 9,744 sites) of all peaks located between -0.5 kb and the TSS were associated with Pol II and P(S5)-Pol II peaks ( Figure S2B ). These data show that p65 peaks found close to TSS are associated with actively transcribed genes, whereas intergenic p65 peaks may have an alternative function ( Figure S2B ). At the genome-wide level, regions encompassing basal or IL-1-inducible p65 sites were usually associated with H3K9me3, H3K9ac, H3K4me1, and H3K27ac marks ( Figure 2D ). There was no change of all four marks after IL-1 stim- ulation within the group of constitutive p65 peaks ( Figure 2D , gray boxes). However, IL-1-inducible peaks showed reduced H3K9me3 levels independent of IL-1 and an increase of H3K9ac only after IL-1 stimulation ( Figure 2D , green boxes). In contrast, across all IL-1-inducible p65 peaks, median H3K4me1 and H3K27ac levels were elevated, whereby H3K4me1 was not regulated by IL-1 and H3K27ac further increased after cytokine treatment ( Figure 2D , green bars). These data suggest that the about 50,000 p65 peaks found at the genome-wide level are either associated with active enhancers or lie directly adjacent to active genes. Moreover, based on their recruitment patterns and the accompanying chromatin modifications they can be divided into two distinct groups: a large, constitutive group of 46,345 peaks and a highly dynamically regulated group of 1,264 p65 binding regions characterized by altered basal and IL-1-inducible p65 recruitment and accompanying histone modifications, suggesting that these chromatin regions confer specific features of cytokine-mediated gene regulation. 
(legend continued on next page)
Genome-wide Identification of IL-1-and p65-Regulated Enhancers Because most p65 peaks were far away from the next gene, we then thought to further characterize the p65 associated enhancer repertoire. High-resolution mapping across all conditions (basal and IL-1-stimulated) revealed 48,133 H3K27ac and 70,225 H3K4me1 peaks. From these data, we derived 35,130 regions as active enhancers, as defined by the presence of both H3K27ac and H3K4me1 marks ( Figure 3A ). IL-1 did not affect both marks simultaneously but did enhance histone marks individually. Specifically, we found 468 DNA regions showing IL-1-inducible H3K4me1 and 1,107 regions showing inducible H3K27ac ( Figures 3A and 3B ). Forty-six out of the 468 active enhancers were associated with p65 peaks, and we designated them as regulated class I enhancers ( Figures 3A and 3C) . Of the 1,107 enhancers, 410 were associated with 469 p65 peaks and were called class II enhancers ( Figures 3A and 3C ). The class II enhancers showed low basal but highly IL-1-inducible p65 recruitment and thus most closely resembled the enhancer regions associated with the chemokine cluster shown in Figure 1 ( Figure 3C ). We therefore focused all further analysis on this subgroup of 410 IL-1-responsive enhancers. Compared to all expressed genes within the data set, the genes next to class II enhancers were regulated by IL-1 as assessed from our microarray and RNA-seq data sets ( Figure 3D ). Motif searches revealed that class II enhancers were enriched for binding sites for NF-kB, Elf3/ 5, FEV, STAT3, SPI1, Jundm2, GCN4, and Fos ( Figure 3E ). Metaprofiles of the class II enhancers showed that basal and inducible H3K27ac was strongly enriched and was peaking symmetrically at regions immediately adjacent to inducible p65 binding sites ( Figure 3F ). Regions of p65 binding showed dips of H3K27ac and H3K4me1 marks, indicating the reduction in nucleosome density after p65 recruitment ( Figure 3F ). H3K27ac enhancer marks covered larger genomic regions after IL-1 stimulation, either due to reduced chromatin compaction or to increased spreading of histone modifications. In unstimulated cells the 410 class II enhancers extended from 400 to 1,500 bp (median of 644 bp), whereas IL-1 stimulation resulted in a further increase in median enhancer width to 1,109 bp ( Figure 3G ). Collectively, the data shown in Figures 2 and 3 identify a class of several hundred cytokine-inducible enhancers that are located upstream of the majority of all IL-1-regulated genes. Moreover, the data suggest that p65, in addition to its classical role in activating promoter-dependent transcription, plays a prominent role in the formation or regulation of these enhancer structures.
Genome-wide Regulation of IL-1-Inducible Enhancers by a TAK1-IKK2-Dependent Pathway To identify the upstream signals involved in gene-and enhancerspecific recruitment of p65 NF-kB, a central part of the IL-1-triggered signals was blocked by the cell-permeable ATPcompetitive kinase inhibitor 5Z-7-oxozeaenol. This compound covalently binds to C174 within the ATP-binding pocket of TAK1, allowing fast inhibition of TAK1 enzymatic activity in cultured cells (Wu et al., 2013) . 5Z-7-oxozeaenol blocked the vast majority of IL-1-inducible genes ( Figure S3A ; Table S2 ). The inhibitory effect on gene expression was almost complete, as exemplified by heatmaps of the top-ranking IL-1-regulated genes ( Figure S3B ) and shown in Table S2 . At the global chromatin level, 5Z-7-oxozeaenol affected only the recruitment of the IL-1-inducible group, but not the constitutive group of p65 peaks ( Figure S3C ). In line with this result, 5Z-7-oxozeaenol suppressed IL-1-inducible IkBa phosphorylation as well as the inducible p65 nuclear translocation and S536 phosphorylation ( Figures S4A and S4B, top) . Accordingly, 5Z-7-oxozeaenol completely inhibited IL-1-inducible IL8 and CXCL2 mRNA expression, demonstrating the relevance of the TAK1 pathway for the regulation of the CXC chemokine locus ( Figure S4C ). Additionally, TAK1 controls further MAPK signaling. Thus, 5Z-7-oxozeaenol also suppressed inducible phosphorylation of JNK, p38, and c-Jun and the expression of c-Jun and c-Fos in a dose-and time-dependent manner ( Figures S4D and S4E ). Under these conditions, little effect of 5Z-7-oxozeaenol was seen on protein levels of ATF2, JunD, and JunB ( Figures S4D and  S4E ). 5Z-7-oxozeaenol also inhibited autophosphorylation of TAK1 ( Figures S4D and S4E ), further indicating its specificity and suitability for suppression of TAK1-mediated signaling in human KB cells. ChIP-seq profiles illustrate that 5Z-7-oxozeaenol suppressed IL-1-inducible p65 recruitment, Pol II loading, and Pol II S5 phosphorylation and H3K27ac at all regions of the IL8 and CXCL2 loci, whereas no effects on H3K4me1 were seen ( Figure 4A ). Moreover, 5Z-7-oxozeaenol inhibited IL-1-inducible p65 recruitment and H3K27ac across the 410 class II enhancers but had no effect on all 35,130 enhancers ( Figure 4B ). Because TAK1 is an upstream regulator of IKK2 (Zhang et al., 2014) , it was interesting to test the consequences of IKK2 inhibition for IL-1-induced global p65-dependent enhancer activation. The specific IKK2 inhibitor PHA-408 (Mbalaviele et al., 2009) inhibited IL-1-inducible IkBa phosphorylation and IL8 and CXCL2 mRNA induction in both HeLa cells (data not shown) and KB cells (Figure 4C ). Similar to 5Z-7-oxozeaenol, the compound inhibited inducible phosphorylation and nuclear translocation of p65 (Figures S4A and S4B, bottom) . Under these conditions, PHA-408 suppressed inducible H3K27ac across the 410 class enhancers ( Figure 4D ). Collectively, these data therefore suggest that a TAK1-IKK2 pathway plays a direct and specific role in IL-1-inducible enhancer activation. Table S3 for statistics for Figures 3B and 3C. two genes flanking the chemokine cluster on chromosome 4 (Figure 5A) . Based on the ChIP-seq profiles, we then designed primer pairs to accurately cover the IL8 and CXCL2 flanking enhancers and promoters as well as negative control regions of both genes as shown schematically in Figure 5B . Three enhancer primer pairs per gene were used to detect the p65 peak or the adjacent (A) KB cells were left untreated or were treated for 30 min with the TAK1 inhibitor 5Z-7-oxozeaenol (5Z, 1 mM), with IL-1 for 1 hr or with 5Z-7-oxozeaenol followed by IL-1 (IL-1 + 5Z). Then ChIP-seq experiments were performed using the antibodies shown in Figure 1 . Profiles for the IL8 and CXCL2 loci are shown; yellow colors indicate samples from cells treated with 5Z-7-oxozeaenol. The presence of NF-kB motifs is indicated by vertical lines underneath the p65 panels. Gray or blue bars indicate genomic areas comprising H3K4me1 and H3K27ac-positive enhancers or class II enhancers, respectively. (B) The mean signal intensities of p65 binding and histone modifications for all 35,130 enhancers versus all 410 class II enhancers were calculated for all conditions described in (A). (C) KB cells were treated for the indicated times with the IKK2 inhibitor PHA-408 (5 mM) or with IL-1 in the indicated combinations. Top: the suppressive effects of PHA-408 on IKK activity and IkBa breakdown were assessed by immunoblotting of whole-cell extracts using antibodies against the phosphorylated and unphosphorylated forms of IkBa. b-actin amounts were determined to control for equal loading. Bottom: in parallel, cells were treated with IL-1 for 1 hr or with PHA-408 (5 mM) as indicated and mRNA expression of IL8 or CXCL2 was quantified by RT-qPCR. Shown is the mean fold regulation ± SEM from three independent experiments. (D) KB cells were treated with vehicle (À, DMSO), IL-1 for 1 hr, or PHA-408 (PH, 5 mM) or combinations of IL-1 and PHA-408 as indicated, and ChIPseq experiments were performed and analyzed as described in (B) using antibodies against H3K27ac. See Table S3 for statistics for Figures 4B and 4D . See also Figures S3 and S4 and Table S2. maxima of H3K27ac or H3K4me1. Quantitative ChIP-PCR experiments were performed to determine p65 recruitment, deposition of constitutive and IL-1-inducible H3K27ac and H3K4me1 histone marks, histone H3 density, and Pol II recruitment at the enhancers and promoters of IL8 and CXCL2 ( Figure 5C , top). Depletion of p65 not only resulted in the absence of enhancer and promoter recruitment of this factor, but also prevented RNA Pol II loading ( Figure 5C , top). Moreover, basal and IL-1-inducible H3K27 acetylation was strongly impaired in the absence of p65, whereas H3K4me1 remained largely unchanged ( Figure 5C, top) . IL-1 treatment also resulted in a reduction of H3 density at the IL8 and CXCL2 promoters, which is an indication of reduced chromatin compaction ( Figure 5C, top) . Suppression of p65 counteracted IL-1 triggered chromatin decompaction ( Figure 5C , top), indicating that p65 is controlling not only histone modifications, but also nucleosome density. The relevance of p65 for inducible H3K27ac was also seen for other arbitrarily selected class II enhancers ( Figures S5A and S5B) , showing the general contribution of this transcription factor for IL-1-regulated H3K27ac. By qPCR, the importance of IKK2 and TAK1 for IL-1-induced p65 recruitment and H3K27ac at the IL8 and CXCL2 loci was also revealed in KB cells pretreated either with PHA-408 ( Figure 5C , bottom) or 5Z-7-oxozeaenol (shp65) or with empty pSuper-Puro. After 2 day selection in puromycin, cells were stimulated with IL-1 for 1 hr or were left untreated. Protein expression of p65 was examined by immunoblots (top) and mRNA expression of IL8, CXCL2, and RELA (p65) by RT-qPCR (bottom). Shown are mean fold changes ±SEM from two independent experiments performed in duplicates. (B) Zoomed-in ChIP-seq profiles for IL-1 regulated chromatin modifications at H3K27ac and H3K4me1 as well as for p65 binding of the IL8 and CXCL2 loci. NF-kB motifs, enhancer regions, and class II enhancers are shown by vertical lines or gray or blue bars, respectively. Numbers 1-10 and black bars indicate six enhancer regions, two promoter regions, and two negative control regions, which were analyzed in detail by subsequent quantitative ChIP-PCRs. (C) Top: vector-transfected or p65 knockdown cells were stimulated for 1 hr with IL-1 or were left untreated. ChIP experiments across the enhancers (primer pairs, 1, 2, 3 for IL8 and 8, 9, 10 for CXCL2) or promoters (primer pairs 5 and 6) or negative control regions (primer pairs 4 and 7) as shown in (B) were performed using the indicated antibodies. Bottom: the same analysis was performed using chromatin from KB cells treated with vehicle (DMSO), PHA-408 (5 mM), or IL-1 (1 hr) in the indicated combinations. Shown are the mean values (% input) ±SEM from at least two independent experiments performed in duplicates. See also Figures S4, S5 , and S6.
( Figure S6A ). The critical contribution of TAK1 to inducible p65 binding, H3K27ac, and chemokine gene expression was confirmed in an independent experimental approach after shRNA-mediated downregulation of TAK1 expression ( Figures   S6B and S6C) . Collectively, the results displayed in Figures 4  and 5 show how the TAK1-IKK2-p65 pathway relays cytosolic signals to chromatin modifications in order to mediate coordinated enhancer and promoter activation of IL-1 target genes. 
The TAK1-p65 Pathway Primes and Coordinates Recruitment of Additional Factors at IL-1-Inducible Enhancers and Promoters
We then thought to unravel the kinetics of proteins assembling in addition to p65 at enhancers and promoters of the IL8 and CXCL2 loci downstream of TAK1 in more detail. We determined the recruitment kinetics of the TFs c-Fos, JunD, c-Jun, ATF2, and FRA1 that are known to recognize AP-1 sites as those found by the motif searches and of the histone acetyl transferase cofactor CBP. Several of these factors had already been implicated in IL8 or CXCL2 gene regulation (Hoffmann et al., 2005) . All TFs and CBP bound to IL8 and CXCL2 at promoters but also to the enhancers (Figures 6A and 6B ). These recruitments were specific according to the low signals in immunoglobulin G controls ( Figures 6A and 6B ) and to lack of binding of any of these factors to the negative control region upstream of the IL8 promoter ( Figures S7A and S7B ), which as shown in Figure 5B lacks H3K27ac and H3K4me1 histone modifications. According to their kinetics of recruitment, we assigned these factors to three groups. Group 1 comprises p65, c-Fos, and CBP, because they showed no significant constitutive binding, a peak of recruitment at 1 hr, and an almost complete removal from promoters and enhancers after 6 hr of stimulation (Figures 6A and 6B) . Group 2 consists of JunD and c-Jun, which showed constitutive binding that was increased after 1 hr of IL-1 treatment and incomplete removal from chromatin at later time points ( Figures  6A and 6B) . Group 3 contains ATF2 and FRA1, which showed constitutive binding that was further increased with a delayed kinetics at 3 hr of stimulation and also incomplete removal from promoters and enhancers after prolonged IL-1 stimulation (Figures 6A and 6B) . Additional experiments showed that P(S5)-Pol II binding most closely mirrored the sharp recruitment profile of p65 and occurred only at IL8 and CXCL2 promoters but not at the enhancers (Figures 6A and 6B) . Interestingly, p65 recruitment was already detectable between 10 and 20 min at IL8 and CXCL2 promoters and occurred with a delay at both chemokine enhancers ( Figures 6A and 6B ). In contrast, there was no difference in the kinetics of p65 removal from the IL8 and CXCL2 promoters/ enhancers (Figures 6A and 6B) . Although this effect is relatively small, this observation would be consistent with a model where p65 binds first to the promoter regions of both chemokine loci and subsequently coordinates additional formation of the promoter/enhancer platforms, perhaps by CBP-mediated progressive acetylation at H3K27. Then, we asked which of these events were under control of TAK1. As shown in Figures 6C and 6D , 5Z-7-oxozeaenol blocked in all cases the IL-1-inducible recruitment of p65 and AP-1 factors and had little if any effect on constitutive chromatin binding of these transcription factors. To investigate a possible role of p65 for IL-1-triggered recruitment of AP-1 family members, p65 knockdown cells were used. Between 15 and 60 min of IL-1-stimulation, p65 knockdown did not affect activation of p38, JNK, or the total expression levels of c-Fos and JunD, two AP-1 proteins that bind to promoters and enhancers of IL8 and CXCL2 loci in KB and HeLa cells ( Figure 7A ). Like in KB cells, c-Fos protein expression and chromatin loading was highly IL-1-inducible, whereas the constitutively expressed JunD protein displayed basal but also IL-1-inducible recruitment to the IL8 and CXCL2 loci (Figures 7A and 7B) . Knockdown of p65 prevented the inducible recruitment of c-Fos, JunD, CBP, and P(S5)-Pol II to the IL8 and CXCL2 loci ( Figure 7B ). In addition, interference with p65 expression also resulted in impaired recruitment of its heterodimeric partner p50 NF-kB ( Figure 7B ). In contrast, knockdown of c-Fos or JunD, which was sufficient to suppress their own chromatin recruitment had no effect on inducible p65 binding ( Figure S7C ), thus identifying p65 as a master transcription factor of inflammatory enhancer activation. Furthermore, knockdown of c-Fos or JunD resulted only in slightly impaired IL-1-induced expression of IL8 or CXCL2 mRNAs ( Figure 7C ). These data indicate that p65 is essential for the assembly of TF collectives and additional cofactors at both promoters and enhancers. The data obtained by the quantitative ChIP-PCR analyses of the IL8 and CXCL2 genomic loci in the various knockdown cells or in cells treated with kinase inhibitors were then normalized and integrated to obtain a comprehensive view on the IL-1-triggered signaling events at the chromatin level. These summarizing analyses corroborate the conclusion that IL-1-inducible H3K27ac is primarily regulated through the TAK1-IKK2-p65 pathway, whereas AP-1 proteins such as cFos and JunD have little effect (Figures 7D and 7E) . Altogether, these data reveal the fundamental role of the TAK1-IKK2-p65 pathway in orchestrating the assembly of promoter and enhancer complexes and the accompanying H3K27ac modifications for driving maximal mRNA expression of IL-1-induced genes.
DISCUSSION
Sterile, cytokine-driven inflammation is the underlying cause of numerous diseases such as rheumatoid arthritis, psoriasis, or gout (Chen and Nuñ ez, 2010) . It has long been known that deregulated gene expression is a hallmark of all inflammatory processes (Bhatt et al., 2012; Medzhitov and Horng, 2009; Hao and Baltimore, 2009) . The receptors and cytosolic pathways orchestrating inflammatory gene expression have been studied in considerable detail (Gaestel et al., 2009) . However, how these pathways transduce their information to chromatin is not well understood.
Here, we identify a large number of IL-1-inducible enhancers and their signal-mediated regulation in epithelial cells. The starting point of our study was the discovery of two enhancer regions flanking a cluster of four highly regulated CXC chemokine genes. In accordance with concurrent studies, we classified these enhancers as active genomic regions due to the simultaneous occurrence of H3K4me1 and H3K27ac marks and to the presence of CBP (Calo and Wysocka, 2013) . However, there were also specific features, in particular, the further, IL-1-dependent upregulation of H3K27ac but not H3K4me1 and the rapid, regulated recruitment of the p65 NF-kB subunit. At the genome-wide level, we report more than 45,000 mostly intergenic p65 binding sites. So far, p65 binding events have been mapped in several other cell types in response to TNF-a or LPS. Using lower resolution ChIP-Chip or ChIP-Pet techniques, 348 or 489 promoternear p65 sites and 209 sites distributed at intergenic regions across chromosome 22 were reported (Lim et al., 2007; Schreiber et al., 2006; Martone et al., 2003) . In more recent deep sequencing studies, the numbers of p65 peaks ranged from 12,250 (dendritic cells) (legend continued on next page) 2013; Yang et al., 2013; Xing et al., 2013; Garber et al., 2012; Jin et al., 2011; Kasowski et al., 2010) . Collectively, these data confirm initial estimates that occupied p65 NF-kB sites are within a range of four orders of magnitude (Natoli et al., 2005) . Thus, in these conditions less than 20% of the 300,000 kB consensus motifs in the human genome are occupied by p65 (Jin et al., 2011) . Our study describes one of the largest arrays of p65 sites currently available. The majority of p65 binding events occur constitutively in line with various studies reporting constitutively occurring nuclear p65 protein (Adli and Baldwin, 2006; Nelson et al., 2004; Birbach et al., 2002) . Accordingly, a recent study mapped >20,000 constitutive and mainly intergenic p65 peaks in transformed B cells (Zhao et al., 2014) . Our subcellular fractionation and high-resolution mapping experiments indicate that most of the nuclear p65 protein is contained within the soluble fraction and only small amounts are stably associated with chromatin. These observations indicate that not only the nuclear entry of p65 is a regulated event, but also the balance between free nuclear versus chromatin-associated p65. These mechanisms are likely to be locus specific and accordingly the p65 protein resides at constitutively occupied and IL-1-induced sites. The majority of p65 binding events occur at intergenic regions devoid of RNA polymerase II because two-thirds of 1,264 IL-1-regulated p65 peaks were localized >20 kb upstream of the next annotated gene. By combining these data with further ChIP-seq and mRNA expression analyses, we identified 410 enhancers, which were regulated by IL-1 at the level of p65 recruitment, H3K27 acetylation, enhancer width, and mRNA expression of neighboring genes. Thus, the genome-wide results resemble all of the features of the CXC chemokine cluster shown in Figure 1 and suggest that this group of enhancers has general relevance for IL-1-mediated gene regulation. Enhancers that display TNF-a-inducible H3K27ac have also been noted recently in fibroblasts, and it will be interesting to analyze if they overlap with class II enhancers described in our study (Jin et al., 2013) . Because the correlation of enhancer marks with p65 occupancy does not prove the functional relevance of the enhancer structures for gene expression, we used kinase inhibitor and p65 knockdown experiments to reveal an essential role for the p65 subunit in enhancer activation and subsequent mRNA transcription at the CXC locus. These data provide strong evidence for p65 as a master regulator of IL-1-inducible H3K27ac. Occurrence of H3K4me1 was independent of p65, suggesting that IL-1-regulated signaling pathways recognize genomic regions that are already premarked as enhancers.
The molecular events connecting cytosolic signaling pathways with enhancer regulation are still incompletely understood (Calo and Wysocka, 2013; Pennacchio et al., 2013) . Here, we identify the kinase TAK1 and its downstream kinase IKK2 as important regulators allowing cytokine-triggered chromatin modification. TAK1 and also IKK2 are essential components of the canonical NF-kB pathway (Hä cker and Karin, 2006) . Inhibition of TAK1 or IKK2 kinase activities with specific small molecule inhibitors suppressed IL-1-induced p65 recruitment and H3K27ac at class II enhancers and accordingly also the IL-1-gene response. Indepth quantitative ChIP-PCR analyses of the CXC loci confirmed the genome-wide data and together with the p65 knockdown effects on enhancer acetylation place a TAK1-IKK2-p65 pathway at the center of signal-mediated enhancer acetylation.
However, TAK1 inhibition will also interfere with IL-1-triggered MAPK signaling (Ninomiya-Tsuji et al., 1999) . At the level of chromatin, 5Z-7-oxozeaenol impaired the IL-1-inducible and (to a lesser extent) the basal enhancer recruitment of c-Jun, JunD, JunB, ATF2, c-Fos, and FRA1 to the CXC chemokine locus. These data define a transcription factor collective that employs TAK1-derived signals to assemble at inflammatory enhancers. Motif searches within IL-1-inducible class II enhancers suggest that they are enriched for NF-kB and AP-1 sites, whereby the motif arrangements; i.e., their relative order, orientation, and spacing, are relatively flexible (M.K. and M.B., unpublished data). Our experiments identify p65 as an essential component governing further TF binding events to these cis elements, because its absence precludes c-Fos and JunD binding as well as CBP recruitment and H3K27 acetylation. In contrast, suppression of JunD and c-Fos expression had little effect on p65-mediated enhancer activation, thus identifying a hierarchy among the transcription factors. Because AP-1 subunits do not serve as pioneering transcription factors, they presumably exert further functions such as the resolution of enhancer activation or shaping the kinetics of IL-1-mediated gene expression. Thus, the relative contribution of the individual AP-1 subunits downstream of TAK1 to enhancer activity and downstream gene activation remains to be determined.
These results raise the question on the mechanisms employed by the enhancer complexes to support inflammatory gene MAPK pathways or expression of NF-kB subunits or AP-1 proteins was analyzed in p65 knockdown or control cells stimulated for various times with IL-1 by immunoblotting of whole-cell extracts using the indicated antibodies. Equal loading was confirmed using antibodies against tubulin. Shown is one out of three experiments. (B) Control cells or p65 knockdown cells (shp65) were stimulated for 1 hr with IL-1 or were left untreated. ChIP-PCR experiments were performed using the indicated antibodies with primers covering the promoter or enhancer regions of the IL8 locus (top) or the CXCL2 locus (bottom) as schematically shown in Figure 5B . The bars show the mean enrichment (% input) ±SEM from at least two experiments performed in duplicates. (C) c-Fos or JunD knockdown or control cells were stimulated with IL-1 for 1 hr or were left untreated. Knockdowns were validated by immunoblotting (top) and mRNA expression of IL8 or CXCL2 was determined by RT-qPCR (bottom). Shown are mean fold changes ± SEM from three (JunD) or two (c-Fos) independent experiments performed in duplicates. (D) ChIP-PCR data covering the IL8 and CXCL2 enhancer and promoter regions from all HeLa cell knockdown experiments ( Figures 5C, S6C , and S7C) were pooled, measurements of H3K27ac and H3K4me1 were normalized to H3 levels, and IL-1-regulated changes were calculated as fold changes relative to vectortransfected control cells. One data point for the CXCL2 locus shown in Figure S7C (shFos ChIP-PCR 3) was omitted due to very low H3 signals, which resulted in misleadingly high ratio values. Shown are the mean changes ± SEM from ten (vector controls), three (shTAK1 and shJunD), or two (shp65 and shFos) independent experiments. (E) Changes in H3 modifications were calculated as in (D) for all experiments using TAK1 (5Z) or IKK2 (PHA-408) inhibitors in KB cells as shown in Figure 5C (bottom) and in Figure S6A . Shown are the mean changes ± SEM from combining four independent experiments for controls and two experiments for each inhibitor. See also Figure S7 . expression. Some enhancers transcribe regulatory RNAs that promote transcription from downstream protein-coding genes Simonatto et al., 2013) . However, based on RNA-seq we did not detect RNA at the enhancers, and we also found only spurious amounts of RNA Pol II associated with the IL8 and CXCL2 enhancers. The enhancers of these two genes are located more than 400 kb apart, and their function might be to promote physical interactions by chromatin loopings. They may extend to the promoter regions of individual genes within the cluster, as suggested by the observation that the NF-kB and AP-1 TF collective is also found at the IL8 and CXCL2 promoters. Additionally, they may contact regions on other chromosomes to form regulatory enhancer archipelagos by multiple longrange chromatin interactions (Spitz and Furlong, 2012; Montavon et al., 2011) . Such inflammatory enhancer landscapes may synergize to provide the very robust and synchronized expression of canonical inflammatory genes as shown in Figure S1 . Indeed, a recent study identified over a million long-range chromatin interactions at 5-10 kb resolution in TNF-stimulated cells (Jin et al., 2013) . Thus, our data provide important clues for further studies directed toward the identification of signals that determine the 3D architecture of chromatin during IL-1-driven inflammation.
In summary, we report a time-dependent IL-1-inducible formation of enhancers, which can be viewed as an epigenetic amplifying or feedforward mechanism by which cells achieve the particularly strong and rapid gene expression responses that are typically observed in cytokine-stimulated cells. In the future, it will therefore be interesting to examine possible polymorphisms within the DNA-binding motifs or in the TF collective that we have identified within the enhancer peaks and subsequent alterations in the enhancer architecture. These changes could also account for chronically ongoing expression of proinflammatory genes in inflammatory diseases.
EXPERIMENTAL PROCEDURES Cell Lines and Materials
HeLa and KB human epithelial carcinoma cell lines have been described (Handschick et al., 2014; Hoffmann et al., 2005) . Recombinant human IL-1a was used at 10 ng/ml in all experiments. 5Z-7-oxozeaenol was from Tocris Bioscience; PHA-408 was from Axon Medchem.
Plasmids and Transfections of Cell Lines
shRNA constructs for p65 (Handschick et al., 2014) , JunD, c-Fos, and TAK1 were prepared in pSuper-Puro or pLKO.1 (shTAK1) backbones. HeLa cells were transiently transfected by the calcium phosphate method and were selected for 48-96 hr with 1 mg/ml puromycin.
Cell Lysis and Immunodetection of Proteins
Whole-cell extracts, cytosolic, soluble nuclear, and insoluble nuclear extracts were prepared and used for immunoblotting as described (Handschick et al., 2014) .
Gene Expression Measurements
All mRNA measurements were performed by RT-qPCR, by Agilent microarrays or by RNA-seq with total RNA as described (Handschick et al., 2014) .
Chromatin Immunoprecipitation and PCR ChIP was performed from formaldehyde crosslinked cells, and DNA was quantified by real-time PCR with SYBR Green as described previously in detail (Handschick et al., 2014) .
Deep Sequencing of Nucleic Acids
Sequencing libraries were prepared and analyzed using Illumina reagents and an Illumina HiSeq2500 machine.
ChIP-Seq, RNA-Seq, and Microarray Analyses and Data Visualization Conversion and alignment of ChIP-seq and RNA-seq reads to the hg19 reference genome followed standard procedures. Visualization of binding profiles, enhancer analyses, motif searches, and data analyses of microarray experiments are described in the Supplemental Information. Statistics for all metaanalyses were calculated using the Wilcoxon signed rank test. In all box plots, black lines indicate medians, boxes the lower and upper quartiles (25% and 75%), and whiskers the minimum and maximum values.
ACCESSION NUMBERS
Microarray, RNA-seq, and ChIP-seq data have been deposited in the NCBI GEO under accession number GSE64224. All ChIP-seq experiments were performed from cell-culture samples generated in parallel, but selected H3K9ac, Pol II, and p65 ChIP-seq data from untreated and IL-1-treated KB cells have been previously published, and the data sets have been deposited to the GEO under accession number GSE52470. 
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
